Posted by Michael Wonder on 08 Jan 2016
Novo Nordisk files for regulatory approval of long-acting factor IX in the EU for the treatment of haemophilia B
7 January 2016 - Nonacog beta pegol is a glycopegylated recombinant factor IX with a significantly improved pharmacokinetic profile, developed for patients with haemophilia B.
For more details, go to: http://www.novonordisk.com/media/news-details.1976981.html
